30 related articles for article (PubMed ID: 35016891)
1. GRM1 Immunohistochemistry Distinguishes Chondromyxoid Fibroma From its Histologic Mimics.
Toland AMS; Lam SW; Varma S; Wang A; Howitt BE; Kunder CA; Kerr DA; Szuhai K; Bovée JVMG; Charville GW
Am J Surg Pathol; 2022 Oct; 46(10):1407-1414. PubMed ID: 35650682
[TBL] [Abstract][Full Text] [Related]
2. Association Between Loss of SATB2 Expression in Inflammatory Bowel Disease Indefinite for Dysplasia and a Diagnosis of Definitive Dysplasia on Follow-up.
Cretara A; Knee A; Mueller J; Jawale R
Am J Surg Pathol; 2022 Aug; 46(8):1137-1141. PubMed ID: 35405720
[TBL] [Abstract][Full Text] [Related]
3. Fibroblastic osteosarcoma: A perplexing entity.
Kaur KP; Kundu S; Chatterjee A; Pal M
J Oral Maxillofac Pathol; 2023; 27(3):573-578. PubMed ID: 38033966
[TBL] [Abstract][Full Text] [Related]
4. SATB2 expression in hematolymphoid neoplasms.
Tiu GC; Natkunam Y; Fernandez-Pol S
J Hematop; 2023 Jun; 16(2):119-122. PubMed ID: 38175442
[No Abstract] [Full Text] [Related]
5. Mesenchymal chondrosarcoma of the head and neck with HEY1::NCOA2 fusion: A clinicopathologic and molecular study of 13 cases with emphasis on diagnostic pitfalls.
Xu B; Rooper LM; Dermawan JK; Zhang Y; Suurmeijer AJH; Dickson BC; Demicco EG; Antonescu CR
Genes Chromosomes Cancer; 2022 Nov; 61(11):670-677. PubMed ID: 35672279
[TBL] [Abstract][Full Text] [Related]
6. Chondroblastoma: An Update.
Chen W; DiFrancesco LM
Arch Pathol Lab Med; 2017 Jun; 141(6):867-871. PubMed ID: 28557595
[TBL] [Abstract][Full Text] [Related]
7. The utility of SATB2 immunohistochemical expression in distinguishing between osteosarcomas and their malignant bone tumor mimickers, such as Ewing sarcomas and chondrosarcomas.
Machado I; Navarro S; Picci P; Llombart-Bosch A
Pathol Res Pract; 2016 Sep; 212(9):811-6. PubMed ID: 27465835
[TBL] [Abstract][Full Text] [Related]
8. [Significance of SATB2 in the pathologic diagnosis of osteosarcoma].
Li M; Cai YP; Lu KY; Chen Y; Zhu X; Yin Y; Tang J
Zhonghua Bing Li Xue Za Zhi; 2016 Sep; 45(9):631-5. PubMed ID: 27646893
[TBL] [Abstract][Full Text] [Related]
9. Special AT-rich sequence-binding protein 2 (SATB2) expression is sensitive but may not be specific for osteosarcoma as compared with other high-grade primary bone sarcomas.
Davis JL; Horvai AE
Histopathology; 2016 Jul; 69(1):84-90. PubMed ID: 26644288
[TBL] [Abstract][Full Text] [Related]
10. SATB2 Expression Is Sensitive but Not Specific for Osteosarcomatous Components of Gynecologic Tract Carcinosarcomas: A Clinicopathologic Study of 60 Cases.
Sangoi AR; Kshirsagar M; Horvai AE; Roma AA
Int J Gynecol Pathol; 2017 Mar; 36(2):140-145. PubMed ID: 27294605
[TBL] [Abstract][Full Text] [Related]
11. SATB2 is not a reliable diagnostic marker for distinguishing between oral osteosarcoma and fibro-osseous lesions of the jaws.
Grad-Akrish S; Rachmiel A; Ben-Izhak O
Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 May; 131(5):572-581. PubMed ID: 33309262
[TBL] [Abstract][Full Text] [Related]
12. SOX9 and SATB2 immunohistochemistry cannot reliably distinguish between osteosarcoma and chondrosarcoma on biopsy material.
Sharma AE; Pytel P; Cipriani NA
Hum Pathol; 2022 Mar; 121():56-64. PubMed ID: 35016891
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous Osteoblastic Osteosarcoma: Report of 2 New Cases Integrated With SATB2 Immunohistochemistry and Review of the Literature.
Falconieri G; Cataldi P; Kavalar R; Štitič V; Luzar B
Am J Dermatopathol; 2016 Nov; 38(11):824-831. PubMed ID: 27043339
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
